These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 18308296)

  • 1. Behavioral alterations in rotenone model of Parkinson's disease: attenuation by co-treatment of centrophenoxine.
    Nehru B; Verma R; Khanna P; Sharma SK
    Brain Res; 2008 Mar; 1201():122-7. PubMed ID: 18308296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease.
    Verma R; Nehru B
    Neurochem Int; 2009 Nov; 55(6):369-75. PubMed ID: 19375462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
    Saravanan KS; Sindhu KM; Senthilkumar KS; Mohanakumar KP
    Neurochem Int; 2006 Jul; 49(1):28-40. PubMed ID: 16490285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA.
    Alam M; Mayerhofer A; Schmidt WJ
    Behav Brain Res; 2004 May; 151(1-2):117-24. PubMed ID: 15084427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats.
    Alam M; Schmidt WJ
    Behav Brain Res; 2004 Aug; 153(2):439-46. PubMed ID: 15265640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
    Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T
    Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ameliorative effect of Sida cordifolia in rotenone induced oxidative stress model of Parkinson's disease.
    Khurana N; Gajbhiye A
    Neurotoxicology; 2013 Dec; 39():57-64. PubMed ID: 23994302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic administration of iptakalim, an ATP-sensitive potassium channel opener, prevents rotenone-induced motor and neurochemical alterations in rats.
    Yang Y; Liu X; Long Y; Wang F; Ding JH; Liu SY; Sun YH; Yao HH; Wang H; Wu J; Hu G
    J Neurosci Res; 2005 May; 80(3):442-9. PubMed ID: 15795934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone.
    Fleming SM; Zhu C; Fernagut PO; Mehta A; DiCarlo CD; Seaman RL; Chesselet MF
    Exp Neurol; 2004 Jun; 187(2):418-29. PubMed ID: 15144868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of glutamate and alpha2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats.
    Alam M; Danysz W; Schmidt WJ; Dekundy A
    Toxicol Appl Pharmacol; 2009 Oct; 240(2):198-207. PubMed ID: 19616571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quercetin up-regulates mitochondrial complex-I activity to protect against programmed cell death in rotenone model of Parkinson's disease in rats.
    Karuppagounder SS; Madathil SK; Pandey M; Haobam R; Rajamma U; Mohanakumar KP
    Neuroscience; 2013 Apr; 236():136-48. PubMed ID: 23357119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. D-beta-hydroxybutyrate protects dopaminergic SH-SY5Y cells in a rotenone model of Parkinson's disease.
    Imamura K; Takeshima T; Kashiwaya Y; Nakaso K; Nakashima K
    J Neurosci Res; 2006 Nov; 84(6):1376-84. PubMed ID: 16917840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of neuroprotection by sodium salicylate in a chronic rotenone model of Parkinson's disease.
    Thakur P; Nehru B
    Neuroscience; 2013 Feb; 231():420-31. PubMed ID: 23159314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible neuroprotective mechanisms of curcumin in attenuating 3-nitropropionic acid-induced neurotoxicity.
    Kumar P; Padi SS; Naidu PS; Kumar A
    Methods Find Exp Clin Pharmacol; 2007; 29(1):19-25. PubMed ID: 17344940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures.
    Testa CM; Sherer TB; Greenamyre JT
    Brain Res Mol Brain Res; 2005 Mar; 134(1):109-18. PubMed ID: 15790535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further evidence of centrophenoxine mediated protection in aluminium exposed rats by biochemical and light microscopy analysis.
    Nehru B; Bhalla P; Garg A
    Food Chem Toxicol; 2007 Dec; 45(12):2499-505. PubMed ID: 17688990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterisation of a novel model of Parkinson's disease by intra-striatal infusion of the pesticide rotenone.
    Mulcahy P; Walsh S; Paucard A; Rea K; Dowd E
    Neuroscience; 2011 May; 181():234-42. PubMed ID: 21277943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic administration of rotenone increases levels of nitric oxide and lipid peroxidation products in rat brain.
    Bashkatova V; Alam M; Vanin A; Schmidt WJ
    Exp Neurol; 2004 Apr; 186(2):235-41. PubMed ID: 15026259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models.
    Takeuchi H; Yanagida T; Inden M; Takata K; Kitamura Y; Yamakawa K; Sawada H; Izumi Y; Yamamoto N; Kihara T; Uemura K; Inoue H; Taniguchi T; Akaike A; Takahashi R; Shimohama S
    J Neurosci Res; 2009 Feb; 87(2):576-85. PubMed ID: 18803299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine D₁ and D₂ receptor subtypes functional regulation in cerebral cortex of unilateral rotenone lesioned Parkinson's rat model: Effect of serotonin, dopamine and norepinephrine.
    Paul J; Kuruvilla KP; Mathew J; Kumar P; Paulose CS
    Parkinsonism Relat Disord; 2011 May; 17(4):255-9. PubMed ID: 21306935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.